670 related articles for article (PubMed ID: 17022220)
1. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution.
Uusijärvi H; Bernhardt P; Ericsson T; Forssell-Aronsson E
Med Phys; 2006 Sep; 33(9):3260-9. PubMed ID: 17022220
[TBL] [Abstract][Full Text] [Related]
2. Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production.
Uusijärvi H; Bernhardt P; Rösch F; Maecke HR; Forssell-Aronsson E
J Nucl Med; 2006 May; 47(5):807-14. PubMed ID: 16644751
[TBL] [Abstract][Full Text] [Related]
3. Low-energy electron emitters for targeted radiotherapy of small tumours.
Bernhardt P; Forssell-Aronsson E; Jacobsson L; Skarnemark G
Acta Oncol; 2001; 40(5):602-8. PubMed ID: 11669332
[TBL] [Abstract][Full Text] [Related]
4. Model of metastatic growth valuable for radionuclide therapy.
Bernhardt P; Ahlman H; Forssell-Aronsson E
Med Phys; 2003 Dec; 30(12):3227-32. PubMed ID: 14713089
[TBL] [Abstract][Full Text] [Related]
5. Translation of dosimetric results of preclinical radionuclide therapy to clinical situations: influence of photon irradiation.
Uusijärvi H; Bernhardt P; Forssell-Aronsson E
Cancer Biother Radiopharm; 2007 Apr; 22(2):268-74. PubMed ID: 17600475
[TBL] [Abstract][Full Text] [Related]
6. Differences among Monte Carlo codes in the calculations of voxel S values for radionuclide targeted therapy and analysis of their impact on absorbed dose evaluations.
Pacilio M; Lanconelli N; Lo MS; Betti M; Montani L; Torres AL; Coca PM
Med Phys; 2009 May; 36(5):1543-52. PubMed ID: 19544770
[TBL] [Abstract][Full Text] [Related]
7. Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres.
Bardiès M; Chatal JF
Phys Med Biol; 1994 Jun; 39(6):961-81. PubMed ID: 15551573
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors.
Bernhardt P; Benjegård SA; Kölby L; Johanson V; Nilsson O; Ahlman H; Forssell-Aronsson E
Int J Radiat Oncol Biol Phys; 2001 Oct; 51(2):514-24. PubMed ID: 11567828
[TBL] [Abstract][Full Text] [Related]
9. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
10. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides.
Goddu SM; Rao DV; Howell RW
J Nucl Med; 1994 Mar; 35(3):521-30. PubMed ID: 8113908
[TBL] [Abstract][Full Text] [Related]
11. Modelling of metastatic cure after radionuclide therapy: influence of tumor distribution, cross-irradiation, and variable activity concentration.
Bernhardt P; Ahlman H; Forssell-Aronsson E
Med Phys; 2004 Sep; 31(9):2628-35. PubMed ID: 15487746
[TBL] [Abstract][Full Text] [Related]
12. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions.
Bouchet LG; Bolch WE; Goddu SM; Howell RW; Rao DV
J Nucl Med; 2000 Apr; 41(4):682-7. PubMed ID: 10768569
[TBL] [Abstract][Full Text] [Related]
13. Production and dosimetric aspects of the potent Auger emitter 58mCo for targeted radionuclide therapy of small tumors.
Thisgaard H; Elema DR; Jensen M
Med Phys; 2011 Aug; 38(8):4535-41. PubMed ID: 21928624
[TBL] [Abstract][Full Text] [Related]
14. Dose per unit cumulated activity (S-values) for e⁻ and beta emitting radionuclides in cancer cell models calculated by Monte Carlo simulation.
Rojas-Calderón EL; Torres-García E; Ávila O
Appl Radiat Isot; 2014 Aug; 90():229-33. PubMed ID: 24814610
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic radionuclides: production and decay property considerations.
Volkert WA; Goeckeler WF; Ehrhardt GJ; Ketring AR
J Nucl Med; 1991 Jan; 32(1):174-85. PubMed ID: 1988628
[TBL] [Abstract][Full Text] [Related]
16. Systemic and locoregional dosimetry in receptor radionuclide therapy with peptides.
Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):288-95. PubMed ID: 17043626
[TBL] [Abstract][Full Text] [Related]
17. Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis.
Zhu X; Palmer MR; Makrigiorgos GM; Kassis AI
Med Phys; 2010 Jun; 37(6):2974-84. PubMed ID: 20632610
[TBL] [Abstract][Full Text] [Related]
18. Monte Carlo dose voxel kernel calculations of beta-emitting and Auger-emitting radionuclides for internal dosimetry: A comparison between EGSnrcMP and EGS4.
Strigari L; Menghi E; D'Andrea M; Benassi M
Med Phys; 2006 Sep; 33(9):3383-9. PubMed ID: 17022234
[TBL] [Abstract][Full Text] [Related]
19. S-factor calculations for mouse models using Monte-Carlo simulations.
Bitar A; Lisbona A; Bardiès M
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):343-51. PubMed ID: 17538523
[TBL] [Abstract][Full Text] [Related]
20. Dosimetry in Peptide radionuclide receptor therapy: a review.
Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G
J Nucl Med; 2006 Sep; 47(9):1467-75. PubMed ID: 16954555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
